TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03977090

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Geptanolimab Injection
Description: GB226 3mg/kg, q2w, iv.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fruquintinib
Description: Fruquintinib 3 or 4 or 5mg,qd,po. 3 weeks-on, 1 week-off
Study: NCT00160680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: * Pharmaceutical form: Tablet~* Concentration: 5 mg~* Route of administration: Oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levocetirizine
Description: * Pharmaceutical form: Tablet~* Concentration: 5 mg~* Route of administration: Oral use
Study: NCT01773070

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-450/ritonavir
Description: ABT-450 coformulated with ritonavir. Drug is not administered -- this study is follow-up for participants previously receiving the drug.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-333
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-267
Description: Drug is not administered -- this study is follow-up for participants previously receiving the drug.
Study: NCT02514629

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT04175327

Intervention type: DEVICE
Intervention: CardioCel implantation
Description: treatment of intracardiac defects; treatment of septal defects; valve and annulus repair; great vessel reconstruction; peripheral vascular reconstruction; suture line buttressing
Study: NCT00708331

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 HEMA Hydrophilic Acrylic Intraocular Lens
Description: 2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
Study: NCT03309891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: subcutaneous injection (weekly or twice-monthly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: subcutaneous injection (weekly or twice-monthly)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-H9
Description: subcutaneous injection (weekly or twice-monthly)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Genotropin
Description: subcutaneous injection (daily)
Study: NCT02514629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone Undecanoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin + Testosterone Undecanoate
Study: NCT03287596

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI ZTE2 sequence
Description: feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI ZTE2 sequence
Description: feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI ZTE2 sequence
Description: feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI ZTE2 sequence
Description: feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
Study: NCT01507896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant factor IX
Description: Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
Study: NCT02179684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Baby-sitter surgery N. fascialis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment and follow-up
Description: Patient´s with Bells´palasy are treated with conventional treatment and follow-up
Study: NCT03316079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chest physiotherapy techniques
Description: Respiratory manual CPT

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical insufflation-exsufflation
Description: CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
Study: NCT03154879

Intervention type: DEVICE
Intervention: Amplitude integrated electroencephalography
Description: Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
Study: NCT01786811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: 1. Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.~2. Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person.
Study: NCT01040325

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TD Vaccine System
Description: TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
Study: NCT03711682

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Wheat Flour
Description: Participants in this group will receive placebo capsules for 12 weeks period. With a 2 g dose in capsules with 500 mg of wheat flour(fortified with iron, niacin, thiamin, riboflavin and folic acid), 1 g in during the breakfast (2 capsules) and the other 1 g (2 capsules) during the dinner.
Study: NCT00654810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Intermittent treadmill walking to near maximal claudication pain three days per week

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking Exercise
Description: Intermittent treadmill walking to near maximal claudication pain three days per week
Study: NCT01562210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.~The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
Study: NCT01900938

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of propofol
Description: Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent bolus injection of propofol
Description: A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Study: NCT00617578

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ATP One Shot ON
Description: The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ATP One Shot OFF
Description: Standard defibrillation shock delivery
Study: NCT02443948

Intervention type: OTHER
Intervention: Vena puncture for blood collection
Description: Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test

Intervention type: OTHER
Intervention: Vena puncture for blood collection
Description: Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test

Intervention type: OTHER
Intervention: Vena puncture for blood collection
Description: Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
Study: NCT01559844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study: NCT05151302

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: computer vision symptom scale (CVSS) questionnaire
Description: Subjects working at VDT for \>20 hours a week and accessing to the Eye Clinic in order to complete an ocular examination and subjects working at the Foundation accessing to the Eye Clinic in order to complete an ocular status evaluation according to Italian Law 81/08 will be asked to self-complete the questionnaire in presence of the attending junior ophthalmologists prior to the visit with the Ophthalmologist, to avoid interference with visit results (communication of bad/good news)
Study: NCT01764165

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High flow of room air
Description: Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
Study: NCT02181803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg
Study: NCT00729508

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 1X 4 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 1X 4 administrations 4 weeks apart

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cat-PAD
Description: Cat-PAD dose 1X 8 administrations 2 weeks apart

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Cat-PAD
Description: Placebo
Study: NCT02181803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8189
Description: MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a total daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 12 mg, 14 mg, 16 mg, 20 mg, or 40 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Base Monotherapy
Description: For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Base Monotherapy
Description: For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Base Monotherapy
Description: For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone \[not to exceed daily dose of 6 mg\], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
Study: NCT04203693

Intervention type: DRUG
Intervention: Tildrakizumab
Description: The study physicians will choose the treatment independently of the enrolment in the study according to routine care.

Intervention type: DRUG
Intervention: Tildrakizumab
Description: The study physicians will choose the treatment independently of the enrolment in the study according to routine care.
Study: NCT01248832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Counseling
Description: Counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by counselors at the Helpline. The protocol used is similar to that proved efficacious. However, to make the counseling culturally appropriate for Asian language speakers, we: capitalizing on first contact, present the Helpline as a credible quit smoking program staffed by experts, avoid the term counseling since it is associated with mental illness, and assume a more authoritative role and directive counseling style. Counseling is proactive (1st call is made by smoker, then subsequent calls are made by the counselor) to help reduce attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) scheduled according to the probability of relapse.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-Help Materials
Description: All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Help Materials
Description: All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
Study: NCT00951041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340272A
Description: Two intramuscular injections

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK investigational vaccine GSK2340269A
Description: Two intramuscular injections
Study: NCT03687190

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai chi
Description: participants were required to receive hospital-based Tai chi training at least once a month, and home-based Tai chi exercise at least three times a week over the next 9 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional medicine
Description: participants without Tai chi training still received routine conventional medicine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: conventional medicine
Description: participants without Tai chi training still received routine conventional medicine
Study: NCT02881723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radio- chemotherapy
Study: NCT02401568

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic CT
Description: Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).

Intervention type: DEVICE
Group type: OTHER
Intervention: Dynamic CT
Description: Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthrography
Description: percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Arthrography
Description: percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
Study: NCT02035800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Patient will received medication as standard of care
Study: NCT02131272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin detemir
Description: Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin NPH
Description: Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet/exercise
Description: Intervention will be performed through family based changes in eating and activity behaviours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet/exercise
Description: Intervention will be performed through family based changes in eating and activity behaviours.
Study: NCT01656551

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: 500 mg/m2 day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 mg/m2 day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2 day 1 every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 60 mg/m2 day 1 every 3 weeks
Study: NCT04474626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Oral, 1 time per day, per predetermined dosed per 28 treatment cycle.
Study: NCT01088139

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
Study: NCT01922115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trospium Chloride
Description: Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03280758

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle Strengthening exercises
Description: Participants will be required to participate in resistance training 3 hours per week.
Study: NCT03188848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPI-3016
Description: Single-dose subcutaneous injection of BPI-3016

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose subcutaneous injection of placebo to match BPI-3016